pharmaphorum
MAY 10, 2021
BioNTech has said it plans to set up a regional base and new manufacturing site in Singapore so that the biotech can keep pace with demand for its mRNA-based coronavirus vaccine and pipeline products in other disease areas. The German firm said the production facility will be able to produce several hundred million doses of mRNA-based vaccine, depending on the requirements of the specific vaccine.
Pharma Times
MAY 10, 2021
Researchers are initiating clinical trials to evaluate whether targeting the CD38 pathway can provide benefit for people with prostate cancer
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
MAY 8, 2021
Annual Drug Patent Expirations for TARCEVA Tarceva is a drug marketed by Osi Pharms and is included in one NDA. It is available from one supplier. There are two patents…. The post New patent expiration for Osi Pharms drug TARCEVA appeared first on DrugPatentWatch - Make Better Decisions.
Pharma Marketing Network
MAY 14, 2021
[link]. The post DarshanTalks: How To Build a Trusted Workforce</br> – May 14, 2021 appeared first on Pharma Marketing Network.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
MAY 10, 2021
A review of side effects reported with coronavirus vaccines by the EMA’s safety committee has uncovered cases of inflammation of the heart in people receiving the Pfizer/BioNTech Comirnaty shot. . The Pharmacovigilance Risk Assessment Committee (PRAC) says it is aware of cases of myocarditis and pericarditis – inflammation of the heart muscle and membrane around the heart – with the vaccine.
Pharma Times
MAY 10, 2021
New data presented at the 2021 European Society of Medical Oncology (ESMO) Breast Cancer virtual congress
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Outsourcing Pharma
MAY 11, 2021
An expert from synthetic biology tech firm Antheia offers ways to rethink current sourcing and manufacturing strategies to tackle current and future woes.
pharmaphorum
MAY 10, 2021
Coronavirus won’t be circulating in the UK by August, according to the outgoing chief of the country’s vaccine rollout scheme, Dr Clive Dix. Dix led the programme from December until he stepped down last week and told the Daily Telegraph that the UK’s vaccination campaign should be enough to protect from the virus and its known variants by the summer.
Pharma Times
MAY 10, 2021
Crysvita is used for the treatment of the rare metabolic bone disease X-linked hypophosphataemia (XLH)
NY Times
MAY 10, 2021
The shots may allow millions of youngsters to get back to school, camps, sleepovers and hangouts with friends.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharma Marketing Network
MAY 12, 2021
According to a stat by Medgadget, “Global Telemedicine Market is valued at USD 27.04 Billion in 2019 and Expected to Reach USD 171.81 Billion by 2026 with a CAGR of 37.2% over the Forecast Period.”. The COVID-19 pandemic seriously accelerated the adoption and implementation of telehealth services, like remote patient monitoring and out-of-office “visits” – a trend that was already on the incline.
pharmaphorum
MAY 11, 2021
Joined up thinking is the key to converting AI-driven advances into real benefits for healthcare systems, say NHSX. Healthcare systems the world over have been facing the same challenges for some time – and the pandemic has only served to compound them. Aging populations, a growing number of people living with long-term conditions, and dwindling resources meant the NHS was already being asked to do more with less before COVID-19 hit.
Pharma Times
MAY 11, 2021
First COVID-19 jab to be approved for emergency use in the US for this younger age group
Outsourcing Pharma
MAY 10, 2021
In this second part of a series on the state of clinical research, a leader from Javara lays out ideas to bring clinical research and care closer together.
Drug Patent Watch
MAY 14, 2021
Annual Drug Patent Expirations for BYDUREON Bydureon is a drug marketed by Astrazeneca Ab and is included in two NDAs. It is available from one supplier. There are thirty-six patents…. The post New patent for Astrazeneca Ab drug BYDUREON appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
MAY 11, 2021
Flagship Pioneering, the VC fund run by Moderna’s co-founder Noubar Afeyan has launched a new biotech Laronde , with an ambitious plan to create a new class of drugs based on Endless RNA. Called eRNA for short, this class of medicines is programmable and can continuously express therapeutic proteins inside the body. This makes the body into a “drug factory”, allowing for long-lasting medicines that allow for repeat redosing and can be administered easily by several routes.
Pharma Times
MAY 10, 2021
First COVID-19 jab developed by a non-Western company to gain this recommendation
Outsourcing Pharma
MAY 13, 2021
A leader from clinical-stage pharma firm NuCana shares promising results for its ProTides therapies and hopes the drugs can elevate outcomes for patients.
Drug Patent Watch
MAY 14, 2021
Annual Drug Patent Expirations for BYDUREON+PEN Bydureon Pen is a drug marketed by Astrazeneca Ab and is included in one NDA. It is available from one supplier. There are twenty-two…. The post New patent for Astrazeneca Ab drug BYDUREON PEN appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
MAY 12, 2021
The care technology firm Birdie has raised $11.5 million to develop its app to help providers deliver elderly care at home. In a statement the UK firm said the fundraiser led by international VC Index Ventures and with participation from Kamet Ventures will be used to grow its business and develop its product. Birdie said its app can help care providers to efficiently deliver more coordinated, personalised and preventative care.
Pharma Times
MAY 11, 2021
Extension of indication expands access to drug for additional cystic fibrosis patients in Great Britain
Outsourcing Pharma
MAY 14, 2021
Novasep has announced a further expansion of its Highly Potent Active Pharmaceutical Ingredients (HPAPIs) manufacturing capabilities at its Le Mans, France site, saying the move strengthens its position as a leading CDMO for the production of innovative and targeted molecules to treat cancer.
Drug Patent Watch
MAY 14, 2021
Annual Drug Patent Expirations for OPSUMIT Opsumit is a drug marketed by Actelion and is included in one NDA. It is available from one supplier. There are four patents protecting…. The post New patent for Actelion drug OPSUMIT appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
MAY 12, 2021
Biosimilars firm Alvotech has filed a lawsuit that challenges AbbVie’s legal defences surrounding the inflammatory disease drug Humira in the US. Alvotech is challenging the patent thicket surrounding Humira, a common ploy in pharma that seems to be particularly effective in the US. Several biological drugs have remained unchallenged on the US market thanks to a legal force-field from supplementary patents, after the main patent has expired and after protection has lapsed in Europe and other cou
Pharma Times
MAY 12, 2021
The final guidance publication comes following an appeal against earlier draft recommendations
Drug Channels
MAY 14, 2021
Today’s guest post comes from Kyle Grimslid, Clinical Solutions Director at CoverMyMeds. Kyle discusses the prescribing trends and policies that emerged in 2020. He highlights the growing importance of pharmacists and the role of technology in improving patient access, affordability, and adherence. Read more in CoveryMyMeds’ 2021 Medication Access Report: Legislative and Regulatory Edition.
Drug Patent Watch
MAY 14, 2021
Annual Drug Patent Expirations for LONSURF Lonsurf is a drug marketed by Taiho Oncology and is included in one NDA. It is available from one supplier. There are four patents…. The post New patent for Taiho Oncology drug LONSURF appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
MAY 10, 2021
As lockdown gradually eases, things are starting to look up but the lasting impact COVID-19 has had on our wellbeing remains. During Mental Health Awareness Month we look at the mental health stigma amongst men. To say we’re in the midst of a mental health crisis is not an exaggeration. Mental health concerns have been increasing for years and have only been amplified by the COVID-19 crisis and national lockdowns.
Pharma Times
MAY 13, 2021
Heart attack patients offered treatment with new technology at the Royal Free Hospital in London
Pharma Mirror
MAY 13, 2021
Industry specialists working on contaminated land are being urged to use the new British Standard BS 10176 for soil sampling. BS 10176 was introduced in August 2020 but tests using old methods, which do not conform to the new standard, are still being accepted by regulators and assessors, which has led to concerns that its use is still only sporadic.
Drug Patent Watch
MAY 14, 2021
Annual Drug Patent Expirations for CINVANTI Cinvanti is a drug marketed by Heron Theraps Inc and is included in one NDA. It is available from one supplier. There are seven…. The post New patent for Heron Theraps drug CINVANTI appeared first on DrugPatentWatch - Make Better Decisions.
pharmaphorum
MAY 12, 2021
NICE has rejected regular NHS funding for Pfizer’s Vyndaqel (tafamidis) for a rare heart condition, although it has left the door open for negotiations if the pharma decides to drop its price. Pfizer had appealed against draft guidance from NICE that rejected Vyndaqel for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) on cost grounds. The pharma unsuccessfully appealed against the decision in first draft guidance issued in June last year, along with patient associations Cardiomyopathy U
Pharma Times
MAY 13, 2021
The 2021 Sales Awards have opened their doors for entry, continuing its legacy of uncovering and rewarding exceptional talent within the pharma sales sector.
Board Vitals - Pharmacist
MAY 12, 2021
As you continue on your journey towards becoming a Licensed Practical Nurse, your next step is to sit for the NCLEX-PN®. While preparing for this difficult exam can be stressful, there are different things you can do to increase your chances for success. We’ve compiled some of the top NCLEX-PN® tips and tricks that will help you get ready for test day.
Drug Patent Watch
MAY 13, 2021
Annual Drug Patent Expirations for AUSTEDO Austedo is a drug marketed by Teva Branded Pharm and is included in one NDA. It is available from one supplier. There are six…. The post New patent for Teva Branded drug AUSTEDO appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
118 
Let's personalize your content